SGLT2 inhibitors are recommended as part of the first-line treatment for heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) by the ESC [9]. This evidence concerns the gene SLC5A2 and heart failure.